Company news

Polyrizon Ltd. (NASDAQ:PLRZ) news

Polyrizon Ltd. news releases on 6ix. Latest, Oct 5, 2026: Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Ltd. (NASDAQ:PLRZ) news

Press releases & updates

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon Announces GMP Manufacturing of Clinical Trial Material with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment